Treg Fundamental Biology Bootcamp Day
Tuesday, May 30

Reviewing the Activity of Tregs in Tissues to Aid Tissue Specific Targeting

9:30 am Characterizing Tregs in their Native Tissues to Inform Localization Interactions

  • David Zemmour Assistant Professor of Pathology, Zemmour Lab, University of Chicago


  • Understanding Treg identity and heterogeneity in tissues
  • Understanding the molecular events in Treg deficiencies leading up to inflammation
  • Pinpointing the location of Tregs in situ in tissues and dissecting cellular interactions

10:00 am Understanding the Mechanism of Action of Treg Therapies to Aid Therapeutic Challenges


  • Determining antigens that stimulate Treg activation to influence therapeutic targeting
  • Uncovering the signals and pathways that influence Tregs to understand how these can be utilized
  • Exploring signals that modify Treg phenotype to assess how these can increase stability

10:30 am Reprogramming Regulatory T Cells to Potentiate Immunotherapy in Tumors


  • Treg enhanced presence and anergy in response to checkpoint therapy
  • Reprogramming Tregs to produce inflammatory cytokines and cooperate with CD8 T cells as opposed to functional blockade of anti-tumor cells
  • Synergyzing Treg reprograming with the standard of care

11:00 am Morning Break & Refreshments

Mastering Biology of Native Tregs to Influence Therapeutic Use

12:00 pm Tissue-Tregs: Regulatory Chameleons

  • Diane Mathis Professor of Immunology, Harvard Medical School


  • Non-lymphoid tissues have unique Foxp3+CD4+ Treg compartments 
  • Tissue-Tregs have distinct phenotypes and dependencies
  • Tissue-Tregs can exert a multiplicity of immunological and non-immunological functions

12:30 pm Round Table: Exploring Biomarkers for Tregs to Clarify Activity In Vivo

  • Fabien Depis Independant Consultant, Independent Consultant


An audience discussion session dedicated to initiating the conversations surrounding your burning questions. Collaborate with your peers to determine best-practice biomarker discovery strategy for Tregs.

  • Using Treg biomarkers to track Tregs in vivo to demonstrate tissue localization
  • Utilizing biomarkers to measure Treg expansion
  • Finding biomarkers to distinguish different Treg subsets and phenotypes 

1:00 pm Lunch Break

Harnessing the Advantages of Alternative Treg Populations to Unlock their Therapeutic Benefits

2:00 pm New Tracking System to Visualize Treg Distribution & Persistence in vivo

  • Fanny Chapelin Assistant Professor, Department of Biomedical Engineering, University of Kentucky


  • Description of MRI contrast agent and Treg labeling strategy
  • In vitro confirmation of Treg labeling via histology and MRI
  • In vivo tracking of systemically infused Tregs

2:30 pm CD8 Treg Control of Antibody Response


  • CD8 Treg target pathogenic CD4 T helper cells through recognition of MHC-E/peptide
  • Identification of TCRs expressed by CD8 Treg leads to understanding of CD8 Treg development
  • Peptide-based approach allows CD8 Treg expansion and inhibition of Tfh-driven antibody responses

3:00 pm Afternoon Break & Refreshments

3:30 pm Bitesize Workshop: Exploiting the Characteristics & Localizations of Treg Subsets to Enhance Tissue-Specific Effects

  • Heth Turnquist Associate Professor, University of Pittsburgh School of Medicine
  • Rahul Sharma Chief Scientific Officer, Slate Bio


A unique opportunity to learn more about alternative Treg subpopulations before putting your learnings into practice through a breakout discussion.

  • Distinguishing the various Treg subset phenotypes and their targeting advantages
  • Perceiving where Treg subsets are enriched in tissues to recognize localizations
  • Harnessing the potential of different subsets to mediate specific therapeutic outcomes.
  • Determining genomic phenotypes and biomarkers of different subsets to measure distribution

5:00 pm Close of Bootcamp